MultiHit mice as a tool to identify cooperating ras effector pathways in tumorigenesis by Hoffmann, Thomas
 
 
 
 
 
 
 
 
 
DIPLOMARBEIT 
 
 
 
 
Titel der Diplomarbeit 
 
 
MultiHit Mice as a Tool to Identify Cooperating 
Ras Effector Pathways in Tumorigenesis 
 
 
 
 
 
 
angestrebter akademischer Grad 
 
Magister der Naturwissenschaften (Mag. rer. nat.)  
 
 
 
 
Verfasserin / Verfasser: Thomas Hoffmann 
Studienrichtung /Studienzweig 
(lt. Studienblatt): 
Molekulare Biologie, A490 
Betreuerin / Betreuer: Prof. Dr. Thomas Decker 
Dr. Robert Eferl 
 
 
 
Wien, im November 2010 Ludwig Boltzmann Institute for Cancer Research (LBI-CR) 
 2 
 
3 
 
4 
 
Acknowledgements 
 
First of all, I would like to thank Robert Eferl for giving me the opportunity to work 
on this exciting project. I have really appreciated that your office is always open for ques-
tions and discussions.  
My special thanks go to Monica Musteanu for her great supervision and endless pa-
tience over the last year. I have really enjoyed working with you on the MultiHit project. 
Furthermore, I would like to thank Monika Schleger for spending her time on criti-
cally reading and improving this manuscript.  
I would also like to thank all members from the LBI-CR, especially Beatrice, Leander 
and Emilio for lots of helpful on- and off-topic discussions.  
Finally, I would like to thank Babsi, my parents and my whole family for endless 
backing and support throughout my studies.  
5 
 
 6 
 
Table of contents 
 
 
1. Abstract ............................................................................................................................................................... 9 
2. Zusammenfassung........................................................................................................................................10 
3. Introduction.....................................................................................................................................................12 
3.1. Cancer: The most common and dreadful disease .....................................................................12 
3.2. The role of Ras GTPases in Cancer ...................................................................................................13 
3.3. Lung cancer..............................................................................................................................................17 
3.4. Mouse models for lung cancer..........................................................................................................17 
3.5. The MultiHit concept ............................................................................................................................18 
3.6. BAC technology for the assembly of the MultiHit construct.................................................20 
4. Aim of the thesis ............................................................................................................................................24 
5. Materials and Methods................................................................................................................................25 
5.1. Mice .............................................................................................................................................................25 
5.2. Mouse experiments...............................................................................................................................25 
5.2.1. Cre-induction upon Tamoxifen injection..............................................................................25 
5.2.2. Cre-induction upon topical Hydroxy-Tamoxifen application .......................................25 
5.2.3. Cre-induction upon poly I:C injection.....................................................................................25 
5.2.4. Lung specific Cre-induction upon AdenoCre inhalation.................................................26 
5.3. Tail DNA isolation...................................................................................................................................26 
5.4. Genotyping...............................................................................................................................................27 
5.5. Southern blot...........................................................................................................................................29 
5.6. RNA isolation and cDNA synthesis ..................................................................................................31 
5.7. Real time PCR...........................................................................................................................................31 
5.8. Western blot.............................................................................................................................................33 
5.9. Histology ...................................................................................................................................................36 
5.9.1. Haematoxylin and Eosin staining.............................................................................................36 
5.9.2. Immunohistochemistry (IHC).....................................................................................................37 
5.10. In situ hybridization............................................................................................................................40 
5.11. Transfection of embryonic stem cells with the MultiHit BAC .............................................46 
5.11.1. BAC purification............................................................................................................................46 
7 
 
5.11.2. Electroporation .............................................................................................................................47 
5.11.3. Genotyping of single cell clones ............................................................................................48 
5.12. Statistics ..................................................................................................................................................49 
6. Results and Discussion.................................................................................................................................50 
6.1. Dosage dependent module activation in mice ..........................................................................50 
6.2. Elevated Ras levels in different tissues...........................................................................................51 
6.3. Different tumor types develop 10 weeks post Tamoxifen injection ..................................52 
6.4. Sebaceous gland tumors.....................................................................................................................54 
6.5. Pancreatic ductal adenocarcinomas...............................................................................................56 
6.6. Lung specific module activation upon AdenoCre inhalation ...............................................57 
6.7. Expression of all three modules in lung and sebaceous tumors..........................................60 
6.8. Single tumor genotyping with in situ hybridization ................................................................61 
6.8.1. Single tumor genotyping of lung tumors .............................................................................61 
6.8.2. Single tumors genotyping of sebaceous gland tumors ..................................................63 
6.9. In vitro activation of the three expression modules .................................................................64 
6.10. Histopathological analysis of lung adenocarcinomas...........................................................66 
7. Conclusion and Outlook .............................................................................................................................68 
9. References ........................................................................................................................................................71 
10. Curriculum vitae ..........................................................................................................................................77 
 
8 
 
1. Abstract 
 
Cancer is the leading cause of death in the world. Over the last years, a lot of effort 
has been made to investigate human cancers and to design therapeutic drugs. Mouse 
models are an important asset in identifying gene mutations related to human diseases.  
Cancer formation is a multi step process. Cells that have acquired several genetic 
and epigenetic changes are positively selected and ultimately induce tumor formation. 
However, mouse models are usually restricted to only one genetic change that can be in-
vestigated at a time. The examination of two or more hits requires complex breeding 
schemes. Even if the resulting mice are viable, this situation does not represent the selec-
tion process in cancer formation.  
Being aware of these difficulties the MultiHit mouse model was designed. It con-
tains three potential oncogenes or gene mutations previously related to cancer. These 
three genes are cloned in off orientation. Upon Cre-activation the modules start to flip be-
tween on and off until the Cre-activity ceases. The flipping leads to one of eight possible 
combinations of activated hits differing from cell to cell. Cells with cooperating hits will be 
selected and eventually be transformed into a tumor cell. 
In this thesis the Ras effector (RasE) MultiHit mouse is characterized. Three muta-
tions of the Ras protein are known to activate exclusively the MAPK, Ral or PI3K pathway, 
respectively. These mutations were used to identify cooperation between these three 
pathways. 
Skin appendage tumors, lung adenocarcinomas and pancreatic ductal adenocarci-
nomas were observed after Cre-activation. The activation events in skin tumors and lung 
tumors were analyzed by in situ hybridization. More than 98% of all skin tumors had all 
three modules switched on. Only one tumor showed single activation of the PI3K pathway. 
In contrast, several different combinations were found in lung tumors. Again, tumors with 
all three modules activated were most frequent but tumors with PI3K only and combina-
tions of MAPK/Ral and MAPK/PI3K were found as well. Interestingly the combination 
Ral/PI3K was never found which suggest that these two pathways together inhibit tumor 
formation.  
The MultiHit model can be used answer different questions in cancer research and 
might represent a test system to evaluate newly identified mutations in human tumors.  
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2. Zusammenfassung 
 
Krebserkrankungen sind mittlerweile die häufigste Todesursache weltweit. In den 
letzten Jahren  wurde an verschiedendsten Krebsarten geforscht und eine Vielzahl von 
neuen Medikamenten entwickelt und getestet. Genetische Mausmodelle sind eines der 
wichtigsten Werkzeuge geworden, um Gene und Mutationen, die in Zusammenhang mit 
der Entstehung von Krebs stehen, zu identifizieren.  
Die Entstehung von Krebs ist ein mehrstufiger Prozess. Zellen die mehrere geneti-
sche und epigenetische Veränderungen erfahren haben und dadurch einen Wachstums-
vorteil bekommen, werden selektioniert und können einen Tumor bilden. Bis jetzt waren 
Mausmodelle auf die Untersuchung einer einzelnen, genetischen Veränderung beschränkt. 
Um mehrere Veränderungen zu erforschen, müssen diese Mäuse aufwendig gekreuzt wer-
den. Auch wenn diese Mäuse überlebensfähig sind, spiegelt dieser Ansatz nicht den natür-
lichen Selektionsprozess bei der Krebsentstehung wider.  
Um diese Schwierigkeiten zu umgehen wurde das MultiHit Mausmodell entwickelt. 
Es enthält drei potentielle Onkogene oder Genmutationen, die im Zusammenhang mit 
Krebs gefunden wurden. Diese drei Gene werden so kloniert, dass anfangs kein Genpro-
dukt davon gemacht werden kann. Bei  Aktivierung der Cre-Rekombinase springen die drei 
Gene zwischen dem inaktiven („off“) und dem aktiven Zustand („on“) hin und her. Lässt die 
Cre-Aktivität nach, stellt sich in jeder Zelle eine der acht möglichen Kombinationen ein. 
Zellen mit kooperiernden Veränderungen werden selektioniert und können letztendlich 
einen Tumor bilden. 
Im Folgenden wurde die Ras Effector (RasE) MultiHit Maus charakterisiert. Es gibt 
drei Ras Mutationen, die jeweils spezifisch nur einen Signaltransduktionsweg anschalten. 
Diese drei Mutanten wurden verwendet um Kooperationen zwischen dem MAPK, dem Ral 
und dem PI3K Signalweg bei der Tumorentstehung zu identifizieren.  
 Tumore der Hautanhangsdrüsen, Adenokarzinome in der Lunge und ductu-
läre Adenokarzinome im Pankreas (Bauchspeicheldrüse) wurden nach Cre-Aktivierung be-
obachtet. Die Aktivierung der drei Expressionsmodule wurde mittels in situ Hybridisierung 
untersucht. Mehr als 98% aller Tumore der Hautanhangdrüsen hatten alle 3 Module gleich-
zeitig aktiviert. Nur ein einziger Tumor hatte den PI3K Signalweg alleine eingeschaltet.  Bei 
den Lungentumoren wurden verschiedene Kombinationen gefunden. Tumore mit Aktivie-
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rung von allen Modulen waren auch hier am häufigsten, aber auch PI3K alleine und Kom-
binationen von MAPK/Ral und MAPK/PI3K führen zur Tumorbildung. Interessanterweise 
wurde die Kombination von Ral/PI3K kein einziges Mal gefunden, was drauf hinweist, dass 
diese Kombination die Entstehung von Tumoren sogar inhibiert.  
Mit dem MultiHit Model können verschiedenste Fragestellungen der Krebsfor-
schung beantwortet werden und es kann dazu verwendet werden um neu identifizierte 
Mutationen zu untersuchen. 
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3. Introduction 
  
3.1. Cancer: The most common and dreadful disease 
 
Cancer is the most common cause of deaths world wide. In 2004 it has claimed 7.4 
million deaths all around the world. This is nearly 13% of all deaths worldwide. In the 
United States cancer is the second most frequent cause of death. Only cardio vascular dis-
eases draw more victims every year. It is estimated that in the US there will be 1.5 million 
new cancer cases and more than 500.000 cancer related deaths in 2010 alone1.  
Cancer is defined as a class of diseases where a group of cells breaks out of the nor-
mal growing habit and starts to grow in an uncontrolled manner. Tumors that invade adja-
cent tissue or spread through blood and lymph vessels are called malignant tumors. If tu-
mor cells detach from the primary tumor and float through the blood system to another 
site in the body it is called metastasis. Usually lymph nodes next to the primary tumor are 
affected but also lung, bone, liver and brain are common metastatic locations for solid tu-
mors2. In contrast benign tumors do not have these abilities and therefore they are much 
less dangerous to the body.  
Generally cell growth and division are tightly regulated to avoid formation of ab-
normal tissue. Over the years two main groups of genes regulating proliferation and cell 
death were identified. Tumor suppressor genes protect the cell from uncontrolled growth 
and can promote apoptosis in the event of aberrant DNA replication. The tumor suppressor 
p53 and the retinoblastoma protein are the best known examples in this group. The loss of 
a tumor suppressor impedes important control mechanisms in the cell and can represent 
the first step in transforming a cell to a cancer cell3. In contrast, oncogenes are dangerous 
for the cell when they are mutated or expressed at high levels. Oncogenes derive from 
normal genes called proto oncogenes. They protect the cell from premature apoptosis and 
promote cell growth and differentiation in a tightly controlled manner. However, aberrant 
activation can set the foundation for transforming a cell4.  
 
Experiments in the early nineties have shown  that tumor formation requires several 
genetic and epigenetic changes (hits) that occur stochastically in a given tissue5,6. Initial hits 
might lead only to increased cell division and hyperplasia. A higher division rate in a given 
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tissue increases the probability of new mutations to occur. Similar to the Darwinian process 
of evolution hits that cooperate with the initial change are positively selected and can 
eventually lead to tumor formation. The mutation rate of human genes is approximately 
2.0 x10-7/gene/division7. It is believed that 5 to 7 genetic changes are needed to transform a 
human cell into a tumor cell. The given mutation rate makes it very unlikely for a cell to 
accumulate several hits in cancer relevant genes. It may also explain the correlation be-
tween the incidence of cancer and age. However, if one of the first hits influences DNA 
damage control or related mechanisms, the probability of developing cancer rises dramati-
cally. This effect is also known as mutator phenotype in early tumor cells8. 
The loss of a tumor suppressor or the activation of an oncogene opens the door for 
more genetic and epigenetic changes. Cancer formation in humans usually takes decades 
which gives a hint to the complexity of the processes required. This multi step process can 
be view as a modified Darwinian selection. Cells with higher proliferation or with less DNA 
damage control are more prone to produce offspring with another genetic change6.  
The analysis of a plethora of different human tumors has shown that a cell has to 
achieve several new capabilities in order to be fully transformed. Six capabilities are pro-
posed to be shared by almost all tumor types6.  
1.) Self-Sufficiency in growth signals 
2.) Insensitivity to antigrowth signals 
3.) Evading apoptosis 
4.) Limitless replicative potential 
5.) Sustained angiogenesis 
6.) Tissue invasion and metastasis 
 
3.2. The role of Ras GTPases in Cancer 
 
GTPases are enzymes with hydrolytic activity to bind and hydrolyze guanosine 
triphosphate (GTP).  These proteins can be divided into to monomeric and hetero trimeric 
GTPases9 . They have functions in signal transduction, control of cell growth and prolifera-
tion and act usually as molecular switches.  
Monomeric GTPases are also called small GTPases because of their molecular 
weight of about 21kD. The Ras superfamiliy makes up for the biggest group of small 
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GTPases and is divided in at least 8 subfamilies called Ras, Rho, Rab, Rap, Arf, Rheb, Rad and 
Rib10. This list is not completed as there are still small GTPases found that do not fit into one 
of these subfamilies11.  
These proteins can act as molecular, binary switches for all kinds of cellular signal-
ing. Ras proteins can be an inactive and in an active conformation. In the inactive state, Ras 
is bound to GDP, while in the active state it is bound to GTP. Guanine nucleotide exchange 
factors (GEFs) are able to load monomeric GTPases with GTP to activate them. Cellular 
events like cell division or proliferation have to be tightly regulated. The intrinsic GTPase 
activity is very low and the GTPase would be active for an undefined amount of time. 
Therefore GTPase activating proteins (GAPs) can stimulate the intrinsic GTPase activity to 
end the signal transduction. However, it was found that in more than 20% of all human 
tumors Ras is point mutated at the amino acid residue 12 or 61 and less frequently at resi-
due 13. Structural analysis of the Ras protein showed that an amino acid exchange in these 
sites impedes the GTPase activity completely. GAPs are not able to inactivate the Ras sig-
naling any more. Uncontrolled Ras signaling can lead to the transformation of the affected 
cell (Figure 1).  
Figure 1: Ras effector pathways. Extracellular signal received and transmitted by G-Protein coupled 
receptors or receptor tyrosine kinases activate and recruit guanosine exchange factors (GEFs). Upon Ras acti-
vation it can activate several effector pathways. The G12V mutation impedes the deactivation of Ras by 
GTPase activation proteins (GAPs). 
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In the human genome there are three Ras genes encoding four different proteins. 
The proteins are HRas (Harvey rat sarcoma viral oncogene homolog), NRas (neuroblastoma 
rat sarcoma viral oncogene homolog) and KRas 1 and 2 (Kirsten rat sarcoma) which are two 
splice variants of the KRas gene. These four proteins are similar in structure and function12. 
Hydrophobic residues like farnesyl or palmitoyl anchor the Ras GTPases to the cytoplasmic 
face of the cell membrane. Ras proteins can be activated by extracellular signals received 
by receptor tyrosine kinases (RTK) or G-Protein coupled receptors. When activated, these 
receptors recruit GEFs to the membrane to activate Ras. Ras proteins have an effector loop 
for binding and activating downstream targets. Three pathways have turned out to be 
most important13.  
1.) The MAPK/Raf pathway 
Figure 2: The MAPK/Raf pathway. Activated Ras can activate the Raf/MEK/Erk signaling cascade. 
 
Upon activation of Ras the conformation of the effector loop changes and recruits 
the GTPase Raf (MAPKKK) to the membrane. Raf becomes active and phosphorylates a sec-
ond kinase, called MEK (MAPKK). MEK is known to be a dual specificity kinase. It phosphory-
lates serin/threonine and tyrosine residues. MEK phosphorylates the extracellular signal-
regulated kinases 1 and 2 (Erk1/2). The two activated Erks, in turn, phosphorylate a plethora 
of molecules that regulate cellular processes like cell growth and differentiation14. 
 
2.) The Ral pathway 
Figure 3: The Ral pathway. Activated Ras can activate the RalGDS/Ral signaling cascade. 
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Ral-A and Ral-B are Ras related GTPases with 58% sequence identity15. Upon Ras ac-
tivation a Ral specific GEF is recruited to the membrane. Upon binding to Ras its conforma-
tion changes and enables RalGDS to activate the two Ral proteins. Ral-A and Ral-B have 
influence on the activity of Cdc42, Rac and other proteins important for cell motility and 
16
PI3K adds a third phosphate group to phosphadityl inositol-(4,5) 
diphos
rylated
way20. The PI3K path-
way is activated by the C40 mutation21. These three mutations display a valuable tool for 
the investigation of the numerous Ras effector pathways.  
 
cytoskeleton organization .  
3.) The PI3K pathway 
Figure 4: The PI3K pathway. Activated Ras can activate the PI3K/Akt signaling cascade..  
 
The third main effector pathway activated by Ras is the phosphatidylinositol 3-
kinase (PI3K) pathway. 
phate (PIP2). The phosphatase Pten is the antagonist of PI3K because is cleaves the 
3´-phosphate of PIP317.  
Similar to the mechanisms described before, activated Ras recruits PI3K to the mem-
brane where it comes in near vicinity to its substrate PIP2.  Many proteins, like Akt (also 
called protein kinase B), can bind PIP3 with a pleckstrin homology domain. Once phosphor-
 and tethered to the membrane Akt activates several proteins that have effects on 
cell survival and cell proliferation. Hence, it can stimulate the increase of the cell volume18.  
A lot of effort has been made to dissect the role of different Ras effector pathways. 
Mutation experiments of the Ras effector loop revealed several amino acid residues crucial 
for the interaction with certain effector proteins. The mutation of S35 in the effector loop 
exclusively activates the MAPK pathway19. Activation of other effector pathways is not pos-
sible anymore. The G37 mutation exclusively activates the Ral  path
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3. Lung cancer 
 
Lung cancer is the deadliest form of all cancer related diseases. About 29% of ma
% of female cancer death are related to lung cancer. In the year 2010 222.000 new 
lung cancer cases and 157.000 lung cancer related death are estimated in the US alone1. 
Two forms of lung cancer make up for more than 97% of human cases22. The non-
small cell carcinomas (NSCLC) can be divided in three subgroups: the squamous cell lung 
carcinoma, adenocarcinoma and large cell lung carcinoma23. These three subtypes account 
for 80% of all lung cancer cases. Small cell carcinom
 17% of all lung cancers24. Carcinoid tumors25, sarcomas26 and other unspecified lung 
tumors are only a minority of new cases each year.  
moking is by far the biggest contributor to lung cancer. About 87% of all lung can-
cer cases in the US are caused by the inhalation of carcinogenic substances in cigarette 
smoke27. 60 different substances that contribute to the carcinogenic potential of cigarette 
smoke have been identified by now28. The lifetime risk among sm
 is about 17.2% for male and 11.2% for female smokers. That is dramatically higher 
compared to the nonsmoker risks of 1.4% and
O
os31 and some viral infections32. 
 
4. Mouse models for lung cancer 
 
Intensive genetic studies on thousands of lung cancer patients have revealed se
vel mutations related to lung cancer. At the same time new ways were discovered to 
manipulate the mouse genome and use transgenic mice as models for human diseases.  
In 1975 Shimkin and Stoner discovered that several inbred mouse strains differ in 
their susceptibility to chemically induced lung cancer33. A polymorphism in the K-Ras gene, 
found only
ice carrying the K-Ras G12D mutation were later shown to develop early onset lung 
cancer35.  
Besides chemical models there are different genetic approaches to investigate lung 
cancer in mice. The use of classical knock out models is limited as some tumor suppr s
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as-
sette is excised and the mutant allele becomes active38. This approach enables the investi-
gati rogression without the influence of other tumors.  
 
3.
e are possibly not even viable. Most 
import  of 
AC transgene that allows the randomized introduction of sev-
eral hits in a given tissue. Cells with cooperating hits should be positively selected and give 
rise to tumors (Figure 5).  
 
 
outs are embryonic lethal. Other mouse strains with not lethal knock outs of tumor 
suppressors like p53, p16 and p19 usually succumb to tumors other than lung tumors36. 
Conditional or inducible expression of mutated alleles in specific tissues circum-
vents the formation of other tumors. One example is a mouse that has a Lox-Stop-Lox cas-
sette in front of the K-Ras G12D allele. This mouse develops normally because the mutated 
allele is not active and one functional KRas copy is sufficient for embryonic development37. 
After inhalation of adenovirus particles expressing Cre-recombinase the Lox-Stop-Lox c
on of lung tumor initiation and p
5. The MultiHit concept 
 
Common cancer mouse models work with knock-out or knock-in vectors where a 
single gene is mutated or turned off. However, only one genetic change can be investi-
gated in these models. To analyze cooperation between two different hits these mice have 
to be crossed according to complex schemes. This is laborious and time consuming. It is 
hardly possible to investigate the cooperation between three hits because several breed-
ing generations would be needed and resulting mic
antly, the forced introduction of mutations does not mimic the evolution process
cancer that selects the most potent cooperating hits. 
Being aware of these difficulties, the MultiHit mouse model was established. This 
model harbors a MultiHit B
 
 
 
 
 
 
 Figure 5: Principle of the MultiHit tumor mouse model. The scheme shows a MultiHit construct 
for three hits (upper drawing). The hits can represent an expression unit for an oncogene or an expression 
unit for the knock-down of a tumor suppressor gene. The expression units are not active since they are 
cloned in an inverted (off) orientation behind a CAGGS promoter (arrow). Each expression unit is flanked by 
loxP sites (triangles) that allow Cre-mediated activation (flipping) of the expression units. Upon transient 
induction of Cre-activity, the three expression modules flip forth and back until Cre-activity ceases. Then, they 
remain either in on- or in off-orientation. Cre-induction in a mouse harboring the MultiHit construct results in 
randomized activation of expression units creating eight genotypically different cell types (lower drawing). 
Combinations of hits that have a synergistic effect in tumorigenesis will be positively selected and can lead to 
tumor formation.  
 
The MultiHit strategy can be employed in different ways to answer biological ques-
tions. The “downstream effector selection” approach has been used to identify require-
ment and cooperations between the MAPK, Ral and PI3K pathways activated by oncogenic 
Ras in different cancers. Oncogenic mutations that constitutively activate Ras proteins are 
commonly found in human tumors and have been used for the generation of cancer 
mouse models. Oncogenic Ras activates several downstream effector pathways. Among 
them, the MAPK, PI3K and Ral pathways are considered to be most important for Ras-
induced tumor formation. However, recent data have suggested that the requirement for 
Ras effector pathways in oncogenic transformation is cell type specific39. 
We have established RasE (Ras effector) MultiHit mice to identify cooperating Ras ef-
fector pathways in cancer formation. The MultiHit BAC for RasE mice contains gene mod-
ules for three different H-RasV12 alleles (S35, G37, C40). These mutants carry not only the 
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oncogenic V12 mutation but also individual mutations in the HRas effector loop that allow 
selective activation of the MAPK (S35), Ral (G37)  and PI3K (C40) pathways. Therefore, Cre 
induction gives rise to eight cell types with differential activation of Ras effector pathways. 
The three expression modules of the MultiHit construct will be called M (MAPK), R (Ral) and 
P (PI3K) to simplify the following explanations.  
 
3.6. BAC technology for the assembly of the MultiHit construct 
 
Bacterial plasmids can be used to clone and amplify heterologous pieces of DNA. 
The size of inserts is limited to several kilo bases. Larger DNA fragments are instable or im-
possible to ligate into the plasmid. Since the genetic mapping of whole genomes requires 
the analysis of thousands of DNA fragments, methods to handle bigger pieces of DNA were 
needed. Murray and Szostak described in 1983 the first yeast artificial chromosome (YAC)40. 
It is a linear, 55kb long plasmid containing all necessary sequences for replication and 
preservation in yeast. The three key features of a YAC are the centromeres, telomeres and 
replication origins. Together this ensures stable duplication and segregation. YACs can be 
used to clone fragments from 100 to 3000kb. However it is difficult to purify their DNA be-
cause the shape is very similar to normal yeast chromosomes and they have been found to 
be not to stable over many generations.  
These problems led to a further search for alternatives to clone large DNA frag-
ments. Bacterial artificial chromosomes (BACs) were the next logical step. The identification 
of several genes in the low copy F-plasmid led to the production of the first BAC41. It con-
sisted of the regulatory genes oriS, repE, parA, and parB. The oriS and repE genes mediate 
the unidirectional replication of the F-plasmid while parA and parB maintain copy number 
at low level (one or two per E. coli genome). A selection marker, like an antibiotic resis-
tance, enables the selection of cells that have taken up a plasmid after transformation. The 
usual insert size for a BAC ranges from 150 to 300kb, but can reach up to 700kb. BACs are 
stable for hundreds of generations and easy to purify with standard kits.  
Recombineering stands for recombination mediated genetic engineering and is a 
method of manipulating BAC DNA42. ET recombination is homologous recombination in E. 
coli mediated by the phage protein pair RecE/RecT43. Inserts have to be flanked by homol-
ogy arms with a minimum length of only 9bp44.  
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The MultiHit construct was cloned in a two step process. It could not be assembled 
by standard cloning techniques because it consists of several repetitive elements. A two 
step cloning protocol was developed that allowed rapid assembly of BAC constructs for 
three hits (Figure 6). 
  
Figure 6: Scheme of the recombineering strategy to generate large MultiHit BAC constructs. (a) 
The first expression cassette, containing only module 1, was integrated in the Collagen 1a1 BAC via ET re-
combination. In a second, C31 recombinase mediated, step the expression cassette containing module 2 
and 3 was integrated. (b) Southern blot analysis using F1 offsprings from the RasE transgenic founder mouse 
Tg(RasE)290Biat and a probe matching the Collagen 1a1 locus. Tail DNA from four wild-type and four BAC-
transgenic mice was used after PCR pre-screening. The BAC used for oocyte injection was loaded as control. 
This analysis demonstrates single copy integration. 
 
In a first ET recombineering step, a vector containing expression module 1 is inte-
grated via homologous recombination into a BAC backbone. A standard integration site in 
an open chromatin region of the Collagen 1a1 BAC was used. Module 1 is flanked by FRT 
recombination sites and chicken 2xHS4 insulator sequences45,46 that should avoid promoter 
interference and promoter suppression effects from neighboring expression units. To-
gether with the insulated module 1, an ampicillin resistance gene (Amp) flanked by ΦC31 
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attB recombination sites, is integrated. Therefore, recombinants can be selected for am-
picillin resistance. In a second step, a vector containing expression modules 2 and 3 is inte-
grated into the BAC via ΦC31 attP recombination47. This recombination event replaces the 
ampicillin resistance gene for the incoming sequence that contains a neomycin resistance 
gene (Neo). Positive recombinants can be screened for loss of ampicillin resistance and 
gain of kanamycin resistance. The resulting construct contains all three expression mod-
ules flanked by chicken 2xHS4 insulators. The whole locus is flanked by FRT recombination 
sites that allow FLP-mediated deletion of the whole construct which might be used to ad-
dress the question of oncogene addiction48. The attL and attR sequences are generated by 
ΦC31 recombination between attP and attB sites. The generation of these two sites makes 
the recombination irreversible and therefore a valuable tool for the manipulation of large 
DNA fragments.  
The transgenic MultiHit mouse was made via pronuclear injection. The completely 
assembled and Not1 linearized BAC was injected into the maternal pronuclei of fertilized 
oocytes. These oocytes were implanted into the uterus of a pseudo pregnant foster 
mother. The resulting founder mice were back crossed to Bl6 background to check for 
germline integration. The F1 offspring was analyzed with PCR. DNA from four wild type and 
four transgenic mice was isolated and used for Southern blot. A Collagen-A probe was used 
to determine if the mice have more than one BAC copy in their genome. Single copy inte-
grants show a wild type band that is twice as strong as the BAC band because of the two 
collagen alleles. All four analyzed mice are single copy integrants. Single copy integration is 
essential since the presence of multiple copies would increase the background activation 
of Ras effector pathways in tumors.  
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Figure 7: The RasE (Ras effector) MultiHit mouse model. (a) Scheme of the RasE MultiHit BAC con-
struct (upper drawing) and detailed schemes of the individual expression modules (lower drawings). (b) 
Primer orientation in module 1 on and off. In the off orientation Primers 1 and 2 cannot form a PCR product 
because they are facing in the same direction. After Cre-mediated activation of the module a PCR product can 
be amplified.  
 
Figure 7 shows the RasE MultiHit construct in detail. The expression modules consist 
of a CAGGS promoter (P), the HRasV12 effector mutants S35, G37 and C40 for activation of 
the MAPK, Ral and PI3K pathways respectively, an IRES (Gtx), a reporter gene (EYFP, dsRed, 
hCD2t) and a SV40 polyadenylation signal (pA). The Ras effector-IRES-reporter-pA se-
quences are flanked by heterotypic loxP sites (black triangles = canonical loxP, blue trian-
gles = lox5171, red triangles = lox2272)49,50. Heterotypic loxP sites were used to avoid Cre-
mediated deletions because they are unable to recombine with loxP sites of another type. 
Additionally the three modules are cloned in an inverse (off) orientation behind the pro-
moter. Therefore, the Ras effector genes are not expressed in the RasE mouse model but 
can be activated by Cre-mediated inversion. 
Activation of the three modules can be followed by PCR using unique signature se-
quences downstream of the Ras effector mutants (blue, green and red bars in Figure 3b). 
When the module is in off orientation primer 1 and 2 are facing in the same direction. 
Therefore no PCR product can be made. However, after Cre-mediated inversion of the 
module the primers can amplify a PCR product.  
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4. Aim of the thesis 
 
RasE RosaCreERT2 mice develop several different tumors between 9 and 12 weeks af-
ter Tamoxifen injection. The most consistent tumors types were skin appendage tumors, 
lung tumors and pancreatic ductal adenocarcinomas. However, it was not know which 
combinations of the three expression modules contribute to these tumors.  
 
The aim of the thesis is the determination of activation events needed to induce 
tumorigenesis in different organs. The activation of the three modules should be investi-
gated on DNA, RNA and protein level. Southern blot and certain PCR strategies can be used 
to determine the state of the three modules on DNA level. To check if mRNA is produced 
from activated modules in situ hybridization and realtime PCR can be used. Activation of 
the three modules should lead to elevated Ras protein levels and higher expression of 
genes regulated by Ras. This can be analysis can be done by immunohistochemistry and 
Western blot. 
 
To be sure that the activation of the three modules is a stochastic event that does 
not prefer some combinations it is necessary to test the activation in vitro, too. Therefore, 
mouse embryonic stem cells are transfected with the RasE MultiHi BAC. After cotransfec-
tion with a Cre-expressing plasmid single cell clones have to be tested for module activa-
tion. If the system is unbiased all possible combinations should arise with approximately 
the same frequency. Hence, if some combinations are selected in lung tissue they should 
not be over represented in the in vitro experiment. 
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5. Materials and Methods 
 
5.1. Mice 
All animal experiments were performed in accordance with Austrian and European 
laws and with the general regulations specified by the Good Scientific Practices guidelines 
of the University of Vienna. Following mouse strains were used: 
 
 RasE MultiHit mice 
 RosaCreERT2 mice51 
 MxCre mice52 
 p53 knock out mice53 
 Pten flox/flox mice54 
 
5.2. Mouse experiments 
5.2.1. Cre-induction upon Tamoxifen injection 
100mg Tamoxifen (Sigma T5648) are dissolved in 10mL sunflower seed oil (Fluka 
88921). RasE RosaCreERT2 mice were injected intraperitoneally with 100μL Tamoxifen (= 
100μg Tamoxifen total) at four to six weeks of age. If needed, mice were repeatedly in-
jected on consecutive days three or five times.   
 
5.2.2. Cre-induction upon topical Hydroxy-Tamoxifen application 
100mg Hydroxy-Tamoxifen (OH-Tamoxifen, Sigma H7904) are dissolved in 10mL 
absolute ethanol (Sigma 16368). An area of about 1.5cm x 2.5cm is shaved on the back of a 
RasE RosaCreERT2 mouse. Using a Gilson pipette 100μL of the OH-Tamoxifen (100μg Ta-
moxifen total) solution is slowly dropped onto the shaved skin. The procedure has to be 
repeated on four consecutive days55. 
5.2.3. Cre-induction upon poly I:C injection 
10mg poly I:C (Sigma P9582) are dissolved in 5mL sterile 0,9% NaCl solution. Before 
use the poly I:C should be heated to 37°C. RasE MxCre mice were injected intraperitoneally 
with 50μL poly I:C (= 100μg poly I:C total) at four to six weeks of age.   
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5.2.4. Lung specific Cre-induction upon AdenoCre inhalation 
Lung application of AdenoCre was performed through intranasal instillation using 
an AdenoCre-CaCl2 precipitate. For AdenoCre-CaCl2 precipitation, 60μL MEM, 2.5μL Ade-
noCre solution (1010pfu/mL; University of Iowa, gene Transfer Vector Core) and 0.6μL CaCl2 
were mixed for each mouse and incubated 20min at room temperature38. AdenoCre inhala-
tion was done by Daniel Schramek in the IMP/IMBA mouse house. 
 
5.3. Tail DNA isolation 
 
Tail digestion buffer: 
50m M  Tris-HCl, pH.8 
100mM  EDTA 
100mM  NaCl 
1%   SDS 
0.5 mg/mL Proteinase K (Sigma P8044) (add to the buffer before use) 
 
 Cut 2cm tail and add 500μl tail digestion buffer 
 Incubate o/n at 56°C 
 Mix 5min in an Eppendorf mixer 
 Add 167μL 6M NaCl 
 Mix 5min in an Eppendorf mixer 
 Spin at 14000rpm for 10min 
 Transfer 500μL supernatant to a new tube 
 Add 334μL isopropanol, mix and spin at 14000rpm for 10min 
 Discard supernatant properly 
 Wash pellet with 1mL 70%EtOH, centrifuge (14000rpm, 10min) and discard su-
pernatant the carefully 
 Air dry pellet (5-10min) 
 Dissolve DNA in 100μL distilled H2O, for 1 hour at 37°C 
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5.4. Genotyping 
 
Reagents used for PCR: Taq DNA polymerase (Roche 11 146 165 001), dNTPs (Fer-
mentas), primers (MWG Biotech), DMSO (Sigma D4540). 
 
Standard PCR mastermix for 1 reaction: 
Template    1μL 
Puffer (+MgCl2)   2.5μL 
DMSO     2.5μL 
dNTPs (10mM each)   0.5μL 
Primer1 (50ng/1μl)   1μL 
Primer2 (50ng/1μl)   1μL 
TaqPolymerase   0.2μL 
H2O     17.3μL (18.3μL if a primer mix is used) 
 25.0μL 
PCR Program: 
 
94°C 2min 1 cycle 
 
94°C 30sec 
55°C 30sec 
72°C 1min 
40 cycles 
 
72°C 10min 1 cycle 
 
Routinely, DNA fragments were analyzed on agarose (Sigma, A9539) gels by elec-
trophoresis. 2% gels were used for fragments between 300bp and 1kb. Bigger fragments 
can be separated in a 1% agarose gel. 1x TAE was used to dissolve the agarose and as run-
ning buffer as well. 
 
 
27 
 
50x TAE (Tris acetate EDTA) buffer: 
242g   Tris (Roth, 5429.2) 
57.1mL  Acetic acid 
100mL  0.5M EDTA (AppliChem, A1103), pH 8.0  
Fill up with distilled H2O to 1L and autoclave. 
 
Below, DNA sequences of primers used for gene-specific genotyping PCRs are listed. 
All oligonucleotides were obtained from MWG Biotech.  
Primer Name Primer sequence 
Cre1 5’-CGGTCGATGCAACGAGTGATGAGG-3’ 
Cre2  5’-CCAGAGACGGAAATCCATCGCTCG-3’ 
Amplicon: 700pb 
Jun1  5’-CTCATACCAGTTCGCACAGGCGGC-3’ 
Jun2 5’-CCGCTAGCACTCACGTTGGTAGGC-3’ 
Amplicon: 450pb 
p53: Neo19 mut. rev. 5’-CATTCAGGACATAGCGTTGG-3’ 
p53: x7 common fwd. 5’-TATACTCAGAGCCCG-3’ 
p53: X6.5 wt rev. 5’-ACAGCGTGGTGGTACCTTAT-3’ 
Amplicon: wt: 450bp, knock out allele: 700bp 
Pten 1 5’-CTCCTCCTACTCCATTCTTCCC-3’ 
Pten 2 5’-ACTCCCACCAATGAACAAAC-3’ 
Amplicon: wt: 200bp, floxed allele: 300bp 
MultiHit1  5’-GCCATCACGAGATTTCGATT-3’ 
MultiHit2 5’-TGTGACACCCCAGCATTAGA-3’ 
Amplicon: 580bp 
MultiHit ON fwd.  5’-GCTAACCATGTTCATGCCTTC-3’ 
Ras S35 rev. 5’-CAGAAACACACCAAGTCTTCCA-3’ 
Ras G37 rev. 5’-ACAACGAGATGAGGACCAGAAT-3’ 
Ras C40 rev. 5’-TGTACTCAAAGCTGGAAGGTGA-3’ 
Amplicon: 750 bp  
Table 1: PCR primer sequences 
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5.5. Southern blot 
 
Genomic DNA was digested with different restriction enzymes. To detect the activa-
tion of the three modules by Southern blot, labeled RNA probes against reporter genes 
were used. To check for single copy integrants after embryonic stem cell transfection a col-
lagen probe was used.  
 
Restr. enzyme RNA Probe Fragment length 
XcmI YFP-Probe 
M1 off: 3536bp 
M1 on: 1774bp 
XcmI dsRed-Probe 
M2 off: 3769bp 
M2 on: 1744bp 
HindIII hCD2t 
M3 off: 3846bp 
M3 on: 2836bp 
 
The probes were labeled with the Prime it II Random Primer Labeling Kit (Stratagene 
300385), according to the manufacturer’s protocol. 
 
 Digest approximately 10μg of genomic DNA, load on a 0.8% agarose gel con-
taining EtBr and run it in TAE at 90V 
 Depurinate the DNA in the gel by rocking it in 0.25M HCl for 20 min.  
 Denature the DNA in the gel by rocking it in 0.5M NaOH/1.5MNaCl  
for 30 min. 
 Blot over night as follows: 
 Set up the blot from bottom to top: 
o Plastic bag 
o 6 sheets Whatman paper soaked in 10xSSC 
o Gel  
o Parablot nylon membrane (GeneXpress) pre-soaked in 10xSSC 
o 4 sheets Whatman paper soaked in 10xSSC 
o 4 sheets dry Whatman  
o Paper towels, approximately 1kg weight 
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 Next day, soak membrane in 50mM NaPi for 20 min rocking 
 Bake for 1 hour at 80°C 
 Crosslink membrane with Stratalinker (Stratagene) 
 
Membrane hybridization: 
 Pre-hybridize membrane in hybridization buffer for 1h at 65 °C.  
 Add probe and hybridize at 65°C overnight 
 Wash membrane with Washing buffer 3 times 20min each, at 65°C 
 Wrap membrane in plastic foil and expose at -80°C, 4-7days 
 
20xSSC: 
175,3g  NaCl 
88,2g  Sodium citrate 
Fill up with distilled H2O to 1L and adjust to pH 7.0.  
 
0.1M NaPi (natrium phosphate buffer) pH 7.2: 
68.4mL  1M Na2HPO4 
31.6mL 1M NaH2PO4 
Fill up 1L with distilled H2O. 
 
Hybridisation buffer: 
0.5M  NaPi pH 7.2 
7%  SDS 
1mM  EDTA 
 
Washing buffer: 
40mM  NaPi pH 7.2 
1%  SDS 
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5.6. RNA isolation and cDNA synthesis 
 
RNA was isolated from organs and tumors with Trizol (Invitrogen) according to the 
manufacturer’s protocol. Genomic DNA contamination in total RNA extracts was digested 
using 10U of DNAse I (Roche 04716728001), for 30 min at 37°C. After DNAse I inactivation at 
70°C for 10min 1μg total RNA was transcribed into c-DNA using the “RevertAid H Minus 
First Strand cDNA synthesis kit” (Fermentas) following the manufacturer’s instructions. 
 
5.7. Real time PCR 
 
An Eppendorf Realplex Mastercycler was used for real time PCR. In contrast to nor-
mal PCR SYBR Green (Roche Diagnostics) is added to the PCR reaction. It enables quantita-
tive detection of the amplicons. RNA was analyzed in triplicates and the expression levels 
of transcripts were calculated with the comparative CT (threshold concentration) method. 
The individual RNA levels were normalized for GAPDH and are depicted as relative expres-
sion values.  
Real time PCR mastermix for 1 reaction: 
Template (cDNA 1:5 diluted in H2O)   5μL 
Puffer (+MgCl2)     2.5μL 
DMSO       2.25μL 
dNTPs (10mM each)     0.5μL 
Primer1 (50ng/1μL)     1μL 
Primer2 (50ng/1μL)     1μL 
CybrGreen (Roche), (diluted 1:100 in DMSO) 0.25μL 
TaqPolymerase (5 Prime, 2200020)   0.1μL 
H2O       15.4μL 
        25.0μL 
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Real time PCR program: 
 
94°C 2min 1 cycle 
 
94°C 30sec 
55°C 30sec 
72°C 1min 
40 cycles 
 
72°C 10min 1 cycle 
 
Followed by melting curve (standard Eppendorf program) 
 
Real time PCR primers 
 
Primer Name Primer sequence 
Gapdh for. 5’-TGTTTGTGATGGGTGTG-3’ 
Gapdh rev. 5’-TACTTGGCAGGTTTCTC-3’ 
Amplicon: 251 bp 
Ras real fwd. 5’-AGCTGATCCAGAACCATTTTGT-3’ 
Ras S35 real rev. 5’-CAGAAACACACCAAGTCTTCCA-3’ 
Ras G37 real rev. 5’-ACAACGAGATGAGGACCAGAAT-3’ 
Ras C40 real rev. 5’-TGTACTCAAAGCTGGAAGGTGA-3’ 
Amplicon: 528 bp 
Table 2: Real time PCR primer sequences 
 
The primer sequences were designed using an on-line available oligo design pro-
gram (Invitrogen) and DNA oligonucleotides were obtained from a commercial supplier 
(MWG Biotech). 
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5.8. Western blot 
 
Protein extraction (the whole procedure has to be carried out on ice): 
 Resuspend homogenized tissue in an appropriate volume of Protein isolation 
buffer containing protease inhibitor cocktail Complete (Roche) and mix well by 
pipetting 
 Shake vigorously at 4°C for one hour 
 Spin extracts at 13000rpm for 15min 
 Transfer protein lysates carefully into a new Eppendorf tube 
 Measure protein concentration with the Bradford method using the Bio Rad 
Protein assay solution (BioRad, 500-0006) according to the manufacturer’s pro-
tocol 
 Before loading, add an apropriate volume of 6x sample loading buffer to the 
desired quantity of protein 
 Immediately incubate at 95°C for 5min 
 Store protein lysates at -80°C. 
 
The proteins (10μg per gel lane) were separated by SDS-polyacrylamide gel electro-
phoresis (SDS-Page) on 10% or 12% gels, using a BioRad apparature. Proteins were trans-
ferred by semi dry technology (BioRad blotting chamber) onto Hybond C-Extra nitrocellu-
lose membrane (Amersham) for big size proteins or Immobilon PVDF membrane (Millipore) 
for small size proteins, for one hour at 60mA per gel. 
 
 After the transfer, incubate membrane in Ponceau S (Fluka, 78376) stain for 5 
min at room temperature (to check transfer efficiency, equal loading and integ-
rity of proteins) 
 Rinse membrane several times with distilled water  
 Incubate membrane with 5% skim milk/1xPBS/0,1%Tween20 or 
5%BSA/1xPBS/0,1%Tween20 blocking solution, for one hour at room tempera-
ture 
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 Dilute the primary antibody in Blocking Solution and incubate o/n at 4°C, while 
rocking 
 Wash membrane with 1xPBS/0,1%Tween20, 3 times, 10min each 
 Dilute secondary antibody in blocking solution without NaN3 (NaN3 inhibits the 
activity of the horse radish peroxidase enzyme) and incubate membrane for 
one hour at room temperature 
 Wash membrane with 1xPBS/0,1%Tween20, 3 times, 10min each 
 Add ECL solution (ECL-Plus Western Blotting detection system, GE Healthcare), 
according to the manufacturers protocol 
 Cover membrane with plastic wrap and expose to CL-xPosure Film (Thermo 
Scientific, 34090). 
 
Western blot stripping: 
 Add 700μL ß-mercapto-ethanol (Sigma, M7522) to 9,3mL Stripping Buffer 
 Incubate membrane with this solution at 42°C for 30min 
 Wash 3 times with 1xPBS/ 0,1%Tween20 to completely remove ß-mercapto-
ethanol  
 Block membrane in Blocking solution at room temperature for 30min 
 Membrane can be re-probed with a different antibody. 
 
Antibodies used for Western blotting: 
 
Antibody name  Dilution  Source 
PanRas   1:200   Santa Cruz Biotechnology, sc-6246 
HSC 70   1:200   Santa  Cruz Biotechnology, sc-7298 
 
Protein isolation buffer: 
25mM   HEPES pH 7.5 
150mM  NaCl 
10mM  EDTA 
0.1%  Tween-20 
0.5%  NP-40 
10 mM  beta-Glycerolphosphate 
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Lower gel (for 2 small gels)  12%   10% 
1.5M Tris pH 8.9   5mL   5mL 
30% Bis-Acrylamid (Sigma)  8mL   6.66mL 
10% SDS    200μL   200μL 
10% APS    100μL   100μL 
Temed    10μL   10μL 
H2O     6.5mL   7.84mL 
 
Upper gel (for 2 small gels): 
1M Tris pH6.7    0.8mL 
30% Bis-Acrylamid   0.8mL 
10% SDS    60μL 
10% APS    60μL 
Temed    4μL 
H2O     4.3mL 
 
6x sample loading buffer:  
Add 6.05g Tris-base to 40 mL H2O. Adjust to pH 6.8. Fill up up to 100mL with H2O. 
Filtrate through a 0.45μm filter. Add 0.4g SDS and store at 4°C up to one month. 
 
7mL   of the upper solution 
3mL   glycerol 
1g   SDS 
0.93g   DTT 
1.2mg   bromophenol-blue 
Add H2O up to 10mL if needed. Store at -20°C 
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5x SDS Electrophoresis buffer: 
15.1g   Tris-base 
72g   Glycin 
5g   SDS 
Fill up to 1L with distilled water. Do not adjust the pH of the stock solution as the so-
lution is pH 8.3 when diluted. Store at 4°C. 
5x Transfer buffer:  
15.15g  Tris 
72 g   Glycin 
Fill up to 1L with distilled water. 
Stripping buffer: 
62,5mM  Tris HCl, pH 6.7 
2%  SDS 
Ponceau S solution: 
0.1%   Ponceau S 
5 %   Acetic Acid 
 
5.9. Histology 
  
Fresh organs were washed with PBS and fixed in 4% buffered formaldehyde (Roti 
Histofix 4%, Promega P087.3) at 4°C o/n. After fixation tissues were dehydrated using 
graded ethanol. Dehydrated organs were embedded in paraffin. Solid paraffin blocks were 
stored at RT. 2μm thick sections of paraffin blocks were generated using a microtome 
(Shandon) and put on glass carrier slides (Superfrost Plus, Menzel-Gläser). 
 
5.9.1. Haematoxylin and Eosin staining 
 Bake paraffin slides for 1h at 60°C 
 Remove paraffin 3 times, 10min in Xylene substitute (Shandon, 9990505) 
 Rehydrate tissue in descending ethanol solutions (100%, 96%, 80%, 70%,  50%) 
for 30s each 
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 dH2O for 5min 
 Haematoxylin (Merck, 1:1 dilution in dH2O) for 10min 
 Wash with tap water 
 Rinse with tap water for 7min 
 Dehydrate tissue in ascending ethanol solutions (50%, 70% for 30s each and 
80% for 20s) 
 Eosin (Roth, 7089.2) 0.1% eosin in 80% ethanol and 0.25% glacial acetic acid) for 
2.5min 
 96% ethanol for 30s 
 100% ethanol for 2min 
 Xylene for 2min 
 Mount with Eukitt (Fluka; 03989) 
 
Eosin staining solution: 
 2mL 10% eosin 
 198mL 80% ethanol 
 500μL acetic acid  
 
5.9.2. Immunohistochemistry (IHC) 
Standard IHC Protocol: 
 Bake slides at 60°C for 1h 
 Remove paraffin for 3 times for 10min in Xylene substitute (Thermo Scientific) 
 Rehydrate tissue in descending ethanol solutions (100%, 96%, 80%, 70%,  50%) 
for 30s each 
 dH2O for 5min 
 For antigen retrieval, boil the sections for 10min in Citrate Buffer (pH 6.0) (DAKO 
S2369), antigen retrieval pH 9.0 (DAKO S2367) or do Proteinase K treatment ac-
cording to the antibody requirements 
 Wash 3x with PBS  
 Peroxidase block with 3% H2O2 in PBS for 15min at room temperature (RT)  
 Wash 3x with PBS 
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 Incubate with Avidin Block (Vector Labs) for 10min at RT  
 Wash 3x with PBS 
 Incubate with Biotin block for 10min at RT (Vector Labs) 
 Wash 3x with PBS 
 Incubate with Superblock (ID labs) for 7min 
 Wash 3x with PBS 
 Incubate with Mouseblock (Eubio MKB-2213) (2 drops in 2.5mL PBS) 
 Wash 3x with PBS  
 Incubate with the 1st antibody diluted in PBS/1% BSA overnight at 4°C in humid 
chamber. 
 Wash 3x with PBS 
 Incubate with secondary anti-polyvalent biotinylated antibody (ID labs) for 
10min at RT  
 Wash 3x with PBS 
 Incubate with streptavidin-HRP (ID labs) for 10min at RT  
 Wash 3x with PBS  
 Develop with AEC Chromogen (ID labs, BP1108) according to manufacturer’s 
protocol 
 Counter stain with 1:5 diluted haematoxylin solution for 15s 
 Mount with Aquatex (Merck) 
 
Superblock, secondary anti-polyvalent biotinylated antibody and streptavidin HRP 
solutions are contained in the IDetect Superstain System kit (ID labs, IDST1007). 
 
Proteinase K antigen retrieval protocol: 
 
Proteinase K (Sigma, P2308) stock solution (20x, 400μg/mL):  
Proteinase K    4mg 
TE Buffer, pH 8.0   10mL 
Mix well, aliquot and store at –20 C. 
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Proteinase K working solution (1x, 20μg/mL):  
Proteinase K Stock Solution (20x) 1mL 
TE Buffer, pH 8.0   19mL 
Mix well. This solution is stable for 1 month at 4 C. For longer storage, aliquot and 
store at –20 °C. 
Incubate tissue slides with the Proteinase K working solution for 10 min at 37°C and 
10 min at RT. Wash 3x with PBS and continue with the Standard IHC protocol. 
 
TE buffer: 
10mM  Tris/HCl pH 8.0 
1mM  EDTA pH 8.0 
 
Antibodies used for IHC with the standard protocol: 
 
Antibody name  Dilution  Source 
Synaptophysin   1:50    Dako Cytomation, A0010 
KI67     1:1000   Novocastra NCL-KI67-P 
CD3     1:300    Neomarkers, RM9107 
F4/80     1:100    AbD Serotec, MCA497G 
Insulin    1:200   Santa Cruz Biotechnology, sc-9186 
PanKeratin   1:100   ThermoScientific, MS-343-R7  
CK7    1:500   Abcam, ab9021 
CK19    1:100   Abcam, ab15463 
CC-10    1:100   Santa Cruz Biotechnology, sc-25555 
SPC    1:100   Santa Cruz Biotechnology, sc-13979 
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5.10. In situ hybridization 
 
In order to obtain RNA probes for in situ hybridization the gene of interest has to be 
cloned into a vector between two RNA polymerase transcription sites (Figure 8). The plas-
mid was linearized with XbaI and HindIII respectively.  
 
Figure 8: Scheme of a vector used for in vitro transcription of RNA probes for in situ hybridiza-
tion. The gene of interest is inserted between a T3 and a T7 RNA polymerase site. For transcription of the 
sense probe the vector is linearized with HindIII and transcribed with the T7 RNA polymerase. For transcrip-
tion of the antisense probe the vector is linearized with XbaI and transcribed with the T3 RNA polymerase.  
 
DNA     20μg (in a max. volume of 16μL) 
Enzyme    2μL 
10x Restriction Buffer  2μL 
Pure H2O up to   20μL 
Digest for 4h or o/n at 37°C. The completeness of the digest was checked on a 1% 
agarose gel containing EtBr.  
 
RNA probe synthesis 
 
linearized DNA (1μg/1μL)    1μL 
5x Transcription buffer (Fermentas)   4μL 
10x DIG RNA Labeling Mix (Fermentas)   2μL 
RNase Inhibitor (Fermentas)    1μL 
RNA polymerase (T3 or T7; Fermentas)  1μL 
DEPC – H2O      9μL (up to 20μL) 
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 Incubate at 37°C , for 2h 
 Increase volume to 50μL with DEPC water and spun trough Pharmacia 
Sephadex g-50 pre-made columns.  
 Check 2μL on a 1% agarose  TAE gel 
 Ratio should be 10:1 RNA to DNA template 
 Aliquot and store the probes at -80°C 
 
Preparation of slides for Hybridization 
 
 Bake slides on a hot plate (60°C) for 30min 
 Allow to cool just until the wax looks solidified  
 
Use DEPC treated solutions for all steps prior to hybridization 
 Dewax in xylene 2x 5min (under the hood)  
Rehydrate to PBS: 
 100% EtOH    5min (hood) 
 100% EtOH  5min 
 75% EtOH (DEPC-H2O) 5min 
 50% EtOH (DEPC-H2O) 5min 
 25% EtOH (DEPC-H2O) 5min 
 PBS – DEPC  5min 
 PBS – DEPC  5min 
 
Hybridization: 
 4% PFA/PBS   10min 
 PBT – DEPC (“1”)  Rinse 
 PBT – DEPC (“2”)  Rinse   
 PBT – DEPC (“3”)  Rinse 
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Antigen Retrieval: 
 Proteinase K (Sigma) in PBS  10min  
(20μL PK (10mg/mL) in 200mL PBS – DEPC)  
 PBT – DEPC (“2”)  5min  
 PBT – DEPC (“3”)  5min   
Fixation: 
 4% PFA/PBS  5min 
 PBT – DEPC (“1”)  Rinse 
 PBT – DEPC (“2”)  5min 
 PBT – DEPC (“3”)  5min 
 
Acetylation:  
 Add 625μL acetic anhydride to 250mL 0.1M TEA (Sigma T1377) shake well and 
use immediately.  15min 
 PBT – DEPC (fresh) Rinse 
 PBT – DEPC (“2”)  5min 
 PBT – DEPC (“3”)  5min 
 Air dry slides 30min or use the oven (50°C) 
 Prepare cassettes and hybridize solutions 
For most RNA-probes prehybridization is not necessary, but in case of high back-
ground the procedure is as following:  
 Put 100μL prewarmed (65°C) of hybridization solution per slide and coverslip 
 Place slides into a humid chamber incubate at 65°C for at least 1h 
Preparing of the probes: 
 Mix 1μL probe – DIG with 100μL hybridization solution per slide and incubate at 
85°C for 3min (not longer or the RNA might get degraded) 
 Add probe and coverslip slides avoiding air bubbles 
 Incubate at 65°C overnight (at least 16 hours) in the water bath 
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Post Hybridization Washes: 
All washing steps are carried out in the water bath and solutions should be pre-warmed. 
 
 Remove coverslips by rinsing in 5x SSC 
 1x SSC/50% Formamide  30min at 65°C 
 TNE    10min at 37°C 
 TNE + RNase A (20μg/mL) 30min at 37°C 
(400μL RNaseA 10mg/mL in 200mL TNE) 
 TNE    10min at 37°C 
 2x SSC    20min at 65°C 
 0.2x SSC    20min at 65°C 
 0.2x SSC    20min at 65°C 
 
Antibody incubation and detection 
 
 MABT    5min at RT 
 MABT    5min at RT 
 
 Block in 20% HISS/MABT (400μL/slide) and incubate 1 hour at RT    
 –DIG–AP (1:2000, Roche) in 2% HISS/MABT (400μL/slide) incubate o/n at 4°C in 
a humidified box (aluminum foil wrapped box with soaked towels) 
 
 MABT    Rinse at RT 
 MABT    5min at RT 
 MABT    5min at RT 
 MABT    5min at RT 
 NTMT pH 9.5   10min at RT 
 
 Add BM purple AP substrate (Roche) 
[as little as possible – just enough to cover the tissue] 
 Incubate at RT for 1 hour – 3 days [at 4°C if the reaction is slower] 
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To stop the reactions: 
 NTMT pH 9.5   Rinse at RT 
 PBS    5min at RT 
 PBS    5min at RT 
 
 Postfix in 4% PFA/PBS for 10 – 20min 
 Rinse in PBS 2 times and then in water 
 Counterstain with nuclear fast red (Roth; N0069.1) for 1min, dehydrate in as-
cending EtOH solutions and embed with Eukitt (Fluka; 03989).  
 
Solutions for in situ hybridization: 
 
MPW-DEPC: 
Add 1 mL DEPC/L distilled water, stir until clear and autoclave. 
 
PBS-DEPC:  
100mL 10xPBS + 900mL MPW-DEPC  
 
Hybridization Solution: 
 
10mM   Tris pH 7.5 
600mM  NaCl 
1mM   EDTA 
0.25%   SDS 
10%   Dextrane sulfate (Amersham; 17-0340-01) 
1x   Denhadt´s  
200μg/mL  yeast tRNA (Gibco) 
50%   Formamide 
Store at -20°C 
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50x Denhardt´s: 
1% (w/v)  Ficoll 400 (Sigma; F2637) 
1% (w/v)  Polyvinylpyrrolidone (Sigma, P5288) 
1% (w/v)  BAS 
In MPW 
 
10x TEA [1M]: 
Add 149.19g TEA in a bottle and fill up to 1L with distilled water.  
 
20xSSC: 
175.3g  NaCl 
88.2g  Sodium citrate 
Fill up with distilled H2O to 1L and adjust to pH 7.0.  
 
5x TNE: 
50mM   Tris pH 7.5 
2.5M   NaCl 
5mM   EDTA 
 
5x MAB 
500mM  Maleic acid 
750mM  NaCl 
Adjust pH to 7.5 with 10M NaOH 
 
1x MABT 
200mL 5x MAB + 800mL distilled water, add 1mL Tween-20 (Sigma; P9416) 
 
NTMT, pH 9.5 
100mM  NaCl 
100mM  Tris pH 9.5 
50mM   MgCl2 
0.1% Tween-20 (Sigma; P9416) 
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5.11. Transfection of embryonic stem cells with the MultiHit BAC 
 
5.11.1. BAC purification 
2mL of LB medium with Neomycin [20μg/mL] (LB-neo medium) were inoculated 
from an E. coli glycerol stock (at -80°C) containing the RasE MultiHit BAC. After over night 
incubation at 37°C 250mL LB-neo medium was inoculated and left shaking for 5-6h. Bacte-
ria were harvested from the culture by centrifugation at 5000rpm for 15min at 4°C. The BAC 
construct was purified with the BAC 100 (Nucleobond, 740 579) kit according to the manu-
facturers protocol. The DNA concentration of the purified DNA was measured and test di-
gests with 6 different restriction enzymes were made.  
 
10μL  BAC [c=0.4μg/μL] 
3μL  enzyme 
3μL  10x buffer 
14μL  H2O   
 30μL, digest o/n at 37°C 
 
Enzymes used: EcoRI, SfiI, SrfI, SdaI, MluI, AscI (Fermentas). 
The 6 digests were separated on a 1% agarose gel and the DNA fragments com-
pared to a previous BAC preparation. All fragments showed the anticipated size. 
 
Before the BAC can be used for electroporation it has to be linearized with the re-
striction enzyme NotI.  
30μL  BAC 
6μL  Buffer “O” (Fermentas) 
3μL  NotI (Fermentas) 
21μL  H2O   
 50μL 
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5.11.2. Electroporation 
One frozen aliquot of mouse embryonic fibroblasts was thawed. The cells were 
propagated in gelatin coated flasks in embryonic stem cell medium (ESC-medium). ECS-
medium is DMEM (PAA, E15-101) supplemented with: 
 
 15% FCS (Sigma, F7524) 
 1x Penicillin/Streptomycine  
 1x nonessential amino acids (PAA, M11-300) 
 1x L-Glutamine 
 1x L-Pyruvat (Sigma, S8636) 
 1x -Mercaptoethanol (1:000 stock in H2O, dilution 1:138) 
 LIF, 1.5mL of LIF containing supernatant  
 
0.1% Gelatin: 
Add 200mg gelatine from porcine skin [Sigma, G1890] to 200mL 1x PBS and autoclave.  
 
The cells of a ~100% confluent 75cm2 flask were trypsinized with 1x Trypsin (PAA, 
L11-004) and one half of the cells was centrifuged (10min at 1.000rpm). The pellet was 
taken up in 800μL sterile PBS and transferred to a 4mm electroporation cuvette (Biozym, 
748040). 10μg linearized BAC is added and electroporation was carried out with the 
GenePulsor Xcell (Biorad) using the following program: 
 
 
settings value 
Voltage [V]  230 
Capacitance [μF] 500 
Resistance [] ∞ 
Cuvette 4mm 
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After the electroporation the cells were diluted 1:10000 with ESC-medium and 
plated on gelatin coated culture dishes. After 5-7 days single cell clones became visible. 24 
different clones were picked and propagated in a gelatin coated 24well plate. When the 
cells reached ~ 100% confluences the cells were trypsinized and 50% was used for DNA 
isolation and 50% was propagated further. The DNA was used for Southern blot analysis to 
check for single copy integrants. Additionally the integrity of the three expression modules 
was checked by PCR. 
One single integrant clone, that showed three intact expression modules, was 
grown to maximum density in a 75cm2 flask. The cells were trypsinized, centrifuged (10min 
at 1.000rpm) and the pellet was taken um in 800μL sterile PBS. 10μg of plasmid of transient 
Cre-expression was added and the cells were electroporated with same program as before. 
 
After the electroporation the cells were plated in low density (dilution between 
1:1000 and 1:10000). The rest of the cells was propagated in a 25cm2 flask and spilt 1:10 
every other day. After 5 passages the cells were frozen in FCS containing 10% DMSO.  
 
5.11.3. Genotyping of single cell clones 
After 5-7 days single cell clones were visible. About 300 clones were picked and 
transferred to gelatin coated 96 well plates. When the medium turned yellow the cells were 
trypsinizied with 30μL 2x Trypsin (PAA, L11-400). After adding 180μL ESC-Medium to the 
wells, 70μL of the cell suspension was transferred to a new gelatin coated plate. The resid-
ual 140μL were transferred to a 96 well PCR plate. The plate was centrifuged for 10min at 
5000rpm and the medium was removed carefully. 100μL NID buffer and 2μL Proteinase-K 
[10mg/mL] was added to each well. 
 
NID Buffer:  
50mM   KCl 
10mM   Tris pH 8.3 
2mM   MgCl2 
0.1mg/mL  gelatin 
0.45%   Nonident P40 (Fluka, 74385) 
0.45%   Tween 20 (Sigma, P9416) 
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The PCR plate was sealed and incubated in a PCR cycler with the following program 
 
 56°C for 3h 
 95°C for 10min  
 Storage at 4°C 
 
After centrifugation (10min at 5000rpm) to pellet the cell debris, 5μL of the ob-
tained solution was used for PCR to check for the activation of the three modules.  
 
5.12. Statistics 
All values are represented as means ± s.e.m.. Statistical analysis was performed us-
ing the student’s t test and a P value below 0.05 was considered significant. Calculation 
was performed using the GraphPad Prism 5 software. 
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6. Results and Discussion 
 
6.1. Dosage dependent module activation in mice 
 
To test the module activation in vivo, RasE Rosa26CreERT2 double transgenic mice 
were injected 1x, 3x and 5x with Tamoxifen. As a control one RasE MultiHit mouse without 
Cre was injected 5x with Tamoxifen and one double transgenic mouse was left untreated. 
Three days after the last injection, mice were killed and DNA was isolated from lung (lu), 
liver (li), spleen (s) and gut (g). The module activation was tested by PCR and showed clear 
dosage dependence (Figure 9). Mice with 5 Tamoxifen injections showed the strongest 
module activation. Mice with three Tamoxifen injections showed a little less activation and 
mice with only one Tamoxifen injection showed weak bands for all three modules. Both 
controls showed no activation at all. This excludes spontaneous recombination in the Mul-
tiHit construct and leakiness of the RosaCreERT2 transgene.  
 
Figure 9: Activation of the MultiHit construct in healthy tissue. PCR analysis for activation of Ras 
effector mutants was performed with DNA from lung (lu), liver (li), spleen (s) and gut (g) of RasE 
Rosa26CreERT2 double transgenic mice after 5x, 3x or 1x Tamoxifen injection. Mice were killed three days after 
the last injection. RasE mice treated 5x with Tamoxifen and untreated RasE Rosa26CreERT2 mice were used as 
controls. wt: wild-type; -: no DNA; +: equimolar plasmid positive control; M: MAPK on; R: Ral on; P: PI3K on; 
PCR for jun was performed as loading control. 
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6.2. Elevated Ras levels in different tissues 
 
Activation of the three expression modules should lead to a considerable increase 
of PanRas concentration in different organs. Protein extracts were made from RasE 
Rosa26CreERT2 double transgenic mice injected 5x, 3x and 1x with Tamoxifen. The proteins 
were separated on an acryl amide gel and blotted on a nylon membrane. The membrane 
was incubated with an antibody detecting all three Ras protein (HRas, NRas and KRas) (Fig-
ure 10).  
Lung and liver extracts did not show an increased amount of Ras protein after Ta-
moxifen injection. This effect may be due to the already high Ras expression levels in these 
organs. Spleen and gut showed dosage depended increase of Ras expression levels. It is 
apparent that the 5x control without Cre has the same amount of Ras, as the wild type con-
trol.  
Figure 10: Western blot analysis for activation of Ras effector mutants. Protein extracts from 
lung (lu), liver (li), spleen (s) and gut (g) of RasE Rosa26CreERT2 double transgenic mice after 5x, 3x or 1x Ta-
moxifen injection were tested for Ras expression levels. RasE mice treated 5x with Tamoxifen and untreated 
wild-type (wt) mice were used as controls. Protein expression of HSC70 was analysed as loading control.  
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6.3. Different tumor types develop 10 weeks post Tamoxifen injection 
 
Rosa26CreERT2 double transgenic mice were injected intraperitoneally with Ta-
moxifen on five consecutive days. These mice rapidly lost weight and became sick between 
4.5 and 8 weeks after injection. The strong Cre-activation leads to several different tumors 
and rapid mortality (Figure 11). For the following experiments mice were injected only 3x 
and 1x with Tamoxifen.  
Figure 11: Different tumor types arise upon 5x Tamoxifen injection. The figure shows HE and cy-
toceratin stainings of a lung, liver and head and neck tumor (not further characterized) that arose six weeks 
after Cre-activation with five consecutive Tamoxifen injections.  
 
Upon 1x Tamoxifen injection three different tumor types arise (Figure 12). Lung 
adenocarcinomas and pancreatic ductal adenocarcinomas were observed with 100% pene-
trance. Skin appendage tumors were observed with about 80% penetrance.  
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 Figure 12: Three different tumor types arise upon 1x Tamoxifen injection in RasE 
Rosa26CreERT2 mice. Lung tumors were visible as focal lesions (arrows in upper middle image) in RasE 
Rosa26CreERT2 mice. Pancreatic tumors (second row, middle and right image) appeared histologically as duc-
tal adenocarcinomas. Moreover, skin appendage tumors developed (lower right image). The macroscopic 
view of two isolated skin appendage tumors demonstrates that this tumor type grew to a considerable size 
and was well encapsulated. A higher magnification of all three tumor types is shown in the right images. No 
tumor formation was observed in untreated age-matched RasE Rosa26CreERT2 mice.  Lung (upper left), pan-
creas (middle left) and skin (lower left) are shown. T: tumor; sk: normal skin  
 
Untreated Rosa26CreERT2 double transgenic mice develop lung adenocarcinomas 
and skin appendage tumor after 38 weeks of age. Pancreatic ductal tumors were never ob-
served (Figure 13). This is most likely due to the spars leakiness of the RosaCreERT2 system. 
Untreated RasE mice, without RosaCre, never developed tumors at all.  
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Figure 13: Tumor formation in untreated RasE Rosa26CreERT2 mice after > 38 weeks. Most un-
treated RasE Rosa26CreERT2 mice developed lung tumors (left image) and skin appendage tumors (right im-
age) but no pancreatic ductal adenocarcinomas (middle image) after >38 weeks of age.  
 
 6.4. Sebaceous gland tumors 
A protocol to activate Cre in a skin specific manner was used to investigate the skin 
appendage tumors in more detail. Hydroxytamoxifen (OH-Tamoxifen) dissolved in ethanol 
was applied atopically on the shaved back skin of RasE Rosa26CreERT2 double transgenic 
mice. This way of Tamoxifen application induced skin appendage tumors with 100% pene-
trance about 8 - 10 weeks after the treatment. Figure 14a shows one of this tumors and the 
immunohistochemical characterization. The upper right image shows that the tumor is 
negative for high molecular weight cytokeratin (HMW CK) which excludes the possibility 
that the tumor is derived from hair follicles. Positive hair follicles are marked with arrows. 
The tumors are also negative for N-Cam. Merkel cell carcinomas are neuroendocrine tu-
mors of the skin56. The negative staining for N-Cam excludes that OH-Tamoxifen induced 
tumors are derived from Merkel cells. The tumors are positive for cytokeratin 7 (CK 7), 
shown in the lower left image. This suggests that the cells of origin are sebaceous gland 
cells. The left inset shows a higher magnification of CK7-positive tumor tissue and the right 
inset shows CK 7 positive cells in normal skin.  
The activation of the three modules on DNA level was checked by Southern blot 
(Figure 14b). Atopic treatment of the skin with OH-Tamoxifen is an inefficient inducer of M, 
R and P since activation was not detectable in the Southern blot. In contrast, skin tumors 
displayed a prominent band for M, R and P activation demonstrating that they arose from 
rare cells after positive selection. Untreated skin and the RasE MultiHit BAC were used as 
control. The mode of tumor induction does not seem to influence the tumor type. Two in-
dividual tumors 8.5 weeks after atopic treatment with OH-Tamoxifen and 10 weeks after 1x 
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Tamoxifen injection are shown in the Southern blot. No differences in histology or South-
ern blot could be detected. The tumor tissue used for DNA isolation was dissected carefully 
to isolate pure tumor tissue. However, the strength of the “off band” depends on the 
amount of surrounding non tumor tissue (e.g. uninduced skin or connective tissue). 
 
Figure 14: Characterization of sebaceous gland tumors. (a) Macroscopic view of a tumor located 
underneath the skin (8.5 weeks after treatment). Tumors were negative for high molecular weight cytokeratin 
(HMW CK; upper right image) as revealed by IHC. HMW CK-positive hair follicles are marked with arrowheads. 
Tumors were negative for N-Cam. Villi from the gut with N-Cam-positive nerves are shown as positive control 
(inset). Tumors were positive for Cytokeratin 7 (CK7; lower right image). (b) Southern blot analysis with skin 
(sk) and tumors (T) from RasE Rosa26CreERT2 mice induced by atopic treatment with 4-OH-Tamoxifen (at.) or 
1x injection of Tamoxifen (i.p.). T: tumor, sk: skin.  
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 6.5. Pancreatic ductal adenocarcinomas 
Pancreatic ductal carcinomas were observed in RasE Rosa26CreERT2 double trans-
genic injected 1x Tamoxifen with 100% penetrance. Figure 15 shows the immunohisto-
chemical characterization of these tumors. The HE staining shows clearly the abnormal ap-
pearance of the pancreas. Insulin producing Langerhans islets are highlighted with arrows 
in the HE and Insulin staining of the untreated tissue. However, the tumors are negative, 
indicating that they do not derive from insulin producing cells. Hence there are still resid-
ual Insulin positive islets visible in the tumor tissue. 
The periodic acidic-Schiff (PAS) staining in the untreated tissue shows the positive, 
mucus producing goblet cells of adjacent gut tissue (arrows). The tumors consist of several 
PAS positive ducts. Ki67, which is a marker for dividing cells, is much more abundant in tu-
mor tissue than in healthy pancreas where only a few cells are positive.  
The tumors are also positive for cytokeratin 7 and 19. Together with the positive 
PAS staining, this is the best hint to the ductal nature of the tumors57. In normal pancreas 
only the bile ducts are positive.  
Because of very high background levels it was not possible to determine the mod-
ule activation in these tumors.  
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Figure 15: Immunohistochemical characterization of pancreatic ductal adenocarcinomas. Pan-
creatic tissue of 1x Tamoxifen treated and untreated RasE Rosa26CreERT2 mice was stained for several markers 
of ductal adenocarcinomas.  
 
6.6. Lung specific module activation upon AdenoCre inhalation 
 
To induce the Cre-recombinase in a lung specific manner, an adenoviral inhalation 
protocol was used. This genetically engineered adenovirus expresses Cre-recombinase 
upon infection of lung cells. The left panel of Figure 16 shows macroscopically visible lung 
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tumor 18 weeks after AdenoCre treatment. These tumors appear as focal lesions positive 
for Pan-Cytokeratin (middle and right panel).    
Figure 16: Lung adenocarcinomas were induced in RasE mice by administration of AdenoCre 
particles. Macroscopic view of a lung 18 weeks after administration of AdenoCre particles (left image). Ar-
rowheads indicate tumors. Gross histology of lung tissue showing lung tumors (arrowheads) as focal lesions 
(middle image). Tumors (arrowheads) stained positive for Pan-Cytokeratin (right image). The inset shows a 
Cytokeratin-positive tumor at higher magnification. 
 
To characterize these adenocarcinomas in detail it is important to determine the cell 
of origin of these tumors. There are several different cell types in the lung. Type I pneumo-
cytes are responsible for the gas exchange in the lung and cover about 95% of the alveolar 
surface. Type II pneumocytes are producing surfactant to reduce the surface tension in the 
alveoli58. Clara cells are found in the epithelium of the small airways, producing substances 
that protect the bronchiolar lining59.  
Figure 17 shows consecutive sections of a lung tumor stained for CC10, a marker for 
Clara cells, and for SP-C, a marker for type-II-pneumocytes. The left image shows the corre-
sponding HE staining of the region. The staining for CC10 shows positive Clara cells in 
bronchi already infiltrated and closed by the tumor. The tumor itself is negative for CC10 
but clearly positive for SP-C.  The observed adenocarcinomas are derived from type-II-
pneumocytes.  
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 Figure 17: Determination of the cell type of origin for the lung tumors. IHC for the clara cell 
marker CC10 and the type-II-pneumocyte marker SP-C in two different lung tumors (upper lung tumor at low 
magnification, lower lung tumor at high magnification) of RasE MultiHit mice. Note that the lung tumors are 
positive for SP-C but negative for CC10. The upper left image shows the corresponding HE staining.  
 
As a next step the module activation in lung tissue was tested. Lung tissue taken 6 
days after AdenoCre inhalation was compared to tissue from mice 12 weeks post infection. 
DNA was isolated from one short term lung and two lungs with beginning tumor formation 
and Southern blot analysis for the three modules was performed (Figure 18). Obviously the 
AdenoCre particles are poor activators of the MultiHit construct as for none of the three 
modules an “on” band is visible. In tissue harvested 12 weeks after AdenoCre inhalation 
there is a clear signal for the three “on” bands. This shows that cells with tumor supporting 
hits are positively selected. 
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 Figure 18: Module activation in lung tissue. Southern blot analysis was performed with lung tissue 
after short-term treatment with AdenoCre particles (6d) and with lung tissue bearing focal lesions (12wks). 
Note that short-term AdenoCre treatment is an inefficient inducer of M, R and P since only a few cells are 
infected by the viral particles. In contrast, a prominent band for M, R and P activation was present tumor-
bearing lung tissue reflecting positive selection of Ras-transformed lung cells. 
 
 
6.7. Expression of all three modules in lung and sebaceous tumors 
 
Another way to check for mRNA levels is real time PCR (rtPCR). RNA was isolated 
from two tumor bearing lung samples and two skin appendage tumors (Figure 19). The 
obtained RNA is transcribed with reverse transcriptase and random hexamer primers into 
cDNA. The real time PCR machine measures the double stranded DNA content after each 
cycle of amplification. The relative expression can be calculated by comparing the meas-
ured values with the expression of a housekeeping gene like GAPDH. The graph shows 
similar expression of all three modules in the individual samples.  
The lower level of MRP expression in lung tissue of MH90 (when compared to 
MH64) is most likely due to lower tumor load. Similarly, the lower level of MRP expression 
in T1 (when compared to T2) could be due to the presence of substantial amounts of non-
tumorigenic tissue (uninduced skin, stroma or inflammatory cells).  
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 Figure 19: RNA expression analysis of tumor-bearing lung tissue and sebaceous gland tumors 
in RasE Rosa26CreERT2 MultiHit mice with realtime PCR. No expression of M, R and P was detected in the 
lung of RasE MultiHit mice without Cre (n.d.). Importantly, Cre-induction led to similar expression levels of M, 
R and P in individual tumor bearing lung tissues and sebaceous gland tumors (T1 and T2).  
 
6.8. Single tumor genotyping with in situ hybridization 
 
In situ hybridization was used to determine the module activation in single tumors. 
Labeled, antisense RNA probes against the coding sequence of the three reporter genes 
(EYFP, dsRed and hCD2t) were used to detect mRNA from the expression modules. The 
antisense probes hybridize to the corresponding mRNA molecules. The RNA probes are 
DIG labeled and can be detected with an anti-DIG antibody. Sense probes are used as 
negative controls to rule out unspecific staining.  
 
6.8.1. Single tumor genotyping of lung tumors 
Figure 20 shows the genotyping of four single tumors (T1-T4). The left images show 
the corresponding HE staining for all four tumors. Tumor T1 is positive for M and P but 
clearly negative for R, whereas tumor T2 is positive for all three modules. Tumor T3 is posi-
tive for M only and T4 is again positive for all three modules (lower panel). The lower im-
ages in both, the upper and the lower, panel show the staining with the sense probes. No 
unspecific staining could be detected in any of the slides.  
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Figure  20: Single tumor genotyping with ISH.  Probes detecting the individual reporter se-
quences EYFP, dsRed and hCD2t were used to detect M, R and P, respectively. ISH analysis of focal lesions 
demonstrates a differential activation pattern (activation in blue) in individual lung tumors. Four tumors (T1-
T4) with different activation patterns are shown. Tumor 1 is positive for M and P, whereas T3 shows activation 
of M only. Tumors 2 and 4 are positive for all three modules Tissue sections hybridized with corresponding 
sense probes were used as control and did not give background signals (lower panels). 
 
The appearance of all seven combinations in 190 analyzed tumors is summarized in 
Figure  21a and b. MRP tumors are by far the most abundant with 85.7%. Tumors induced 
by P activation alone came up in 6.6% of all cases, followed by MR and MP tumors. M and R 
tumors came up only once or twice, respectively and the combination RP was never found. 
Figure 21c shows the comparison of M, R and P activation in non-MRP tumors. From the 
activated single modules only P is a very good tumor inducer whilst the individual activa-
tion of M and R was only found once or twice, respectively.  
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Figure 21: Analysis of module activation in 190 single tumors. (a) “Activation map” of M, R and P 
in lung tumors of 7 RasE MultiHit mice after AdenoCre treatment. The number and percentage of tumors 
positive for M, R and P combinations is summarized in the table. Red means module “off”, green means mod-
ule “on”. (b) Tumors with one or two activation events are indicated as non MRP tumors. n.d.: not detectable. 
(c) Comparison of M, R and P activation in non MRP tumors. Gray areas in the bars indicate tumor numbers 
with single activation events M, R or P. M and R need cooperating activation events (white areas in bars indi-
cate tumor numbers harboring M, R or P plus cooperating activation events).  
 
 
6.8.2. Single tumors genotyping of sebaceous gland tumors 
In situ hybridization was used to check the module activation on RNA level  
(Figure 22). The vast majority of tumors analyzed showed activation of all three tumors. 
However, one tumor out of 50 showed only activation of P.  
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Figure 22: ISH analysis of sebaceous gland tumors. 98% of all sebaceous gland tumors showed 
activation (blue staining) of all three expression modules (upper row). Only one tumor out of 50 showed a 
differen
Most of the clones have all three modules in off orientation because the transfec-
tion efficiency is only 10 - 12%. This is a situation mimicking the low infection efficiency of 
AdenoCre particles in the lung. The gel shows one MRP, one MR, one P and one R clone. 
The results of 13 similar experiments are summarized in Figure 23b. It shows clearly that all 
possible combinations can be found. RP and P clones are a little more frequent than the 
others. However, the RP combination was never found in vivo which suggests selection of 
certain combinations. Moreover, there was no overrepresentation of ES subclones with the 
MRP genotype that was frequently found in lung tumors. These data indicate that all pos-
sible Ras effector combinations were present in the lung of RasE mice after AdenoCre 
treatment but certain combinations are selected and give rise to tumors.  
t activation pattern (lower images, just P activated). 
 
6.9. In vitro activation of the three expression modules  
 
To exclude biased Cre-mediated activation effects the MultiHit construct was tested 
in vitro first. Mouse embryonic fibroblasts (HM1) containing a single copy of the MultiHit 
BAC were transfected with a Cre-expression plasmid. The cells were plated in low density 
and single cell clones were tested for module activation with PCR. Figure 23a shows a rep-
resentative experiment with twenty two tested clones. Primers for Jun were used for the 
loading control.  
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Figure 23: In vitro activation of the MultiHit construct in embryonic stem cells (ESC). PCR analy-
sis of ESC clones excluded substantial Cre-biased activation effects. Transgenic embryonic stem (ES) cells with 
a single integration of the RasE MultiHit BAC were generated, transiently transfected with a Cre-expression 
plasmid and plated at low density in culture dishes. (a) After colony formation, individual ESC clones were 
used for NA isolation and genotyped by PCR (one representative experiment is shown); -: no DNA; +: equi-
molar plasmid positive control, M: MAPK on; R: Ral on; P: PI3K on;. (b) Summary of 13 PCR experiments with 
ESC clones. 
 
 
 
 D
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6.
he nu-
clear/c
l and MAPK/PI3K promotes lung cancer induction (yellow). Cooperation between 
APK, Ral and PI3K not only induces lung tumor formation but also promotes invasiveness 
reen).  
 
 
10. Histopathological analysis of lung adenocarcinomas 
 
With support of the lung pathologist Helmuth Popper (Medical University of Graz) 
lung tumors with different module combinations were analyzed for their histopathological 
appearance (Figure 24). 29 MRP and 29 non MRP tumors were analyzed. Some MRP tumors 
are invasive and display an acinar architecture whereas non MRP tumors are never invasive 
and show no clear acinar architecture. Figures 24c and 24d show invasive MRP tumors. 
Newly formed stroma was detected by Movat pentachrome-staining60. Figure 24e depicts 
non-invasive P tumors growing into bronchi (upper left and upper right images) but re-
specting the blood boundary (arrowheads in upper middle image). Mixed solid and acinar 
tumor architecture of a P tumor is showed in the lower left and middle images of figure 
24e. Low and high-grade in-situ carcinomas could be discerned based on t
ytoplasmic ratio and the presence or absence of large granules within the cytoplasm 
(lamellar bodies). The lower right picture shows one of the high-grade MP tumors.  
Figure 24f summarizes the cooperations found between the three Ras effector path-
ways. It looks like Ral prevents PI3K-induced lung cancer formation (red) because this com-
bination was not found in one of the lung tumors. PI3K alone has turned out to be the most 
effective tumor inducer upon the three effectors. To a lower extent cooperation of 
MAPK/Ra
M
(g
 
 
Figure 24: Histopathological evaluation of lung tumors. 29 MRP tumors and 29 non MRP tumors 
were histopathologically analysed for invasiveness (a) and tumor architecture (b). (c) Invasive acinar MRP 
tumor with carcinoma cells infiltrating a desmoplastic stroma. The inset represents Movat pentachrome-
staining with newly formed tumor stroma in green. (d) Invasive acinar MRP carcinoma with desmoplastic 
stroma (S) in the center (left image and third image from the left). Presence of newly formed tumor stroma 
was confirmed by Movat pentachrome-staining (right image; newly formed stroma in green). Invasion oc-
curred in this central area. Higher magnification demonstrated growth into bronchi (arrowheads) and estab-
lishment of tumor blood vessels (neoangiogenesis; second image from the left). (e) Examples of non MRP 
tumors.. (f) Summary of Ras effector pathway cooperations in lung tumorigenesis.  
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7. Conclusion and Outlook 
 
In summary, the described results prove that the MultiHit construct is working in vi-
tro and, as well, in vivo. The in vitro experiments showed that all eight combinations are 
technically possible after Cre-activation and none of the eight possible combinations was 
overrepresented.   
We have established a MultiHit mouse model that mimics the positive selection 
process for cooperative hits in tumor formation. This model can be used in different ex-
perimental setups. We employed the MultiHit approach to investigate Ras downstream 
effector pathways MAPK (M), Ral (R) or PI3K (P) in lung cancer formation of mice. Our data 
indicate that lung cancer in mice is induced by Ras effector cooperativities with the follow-
ing potency: MRP > P > MR > MP > M > R > RP.  
Being aware of the difficulty to confer mouse data on humans, our analyses suggest 
that combined inhibition of MAPK and PI3K pathways might be the most powerful treat-
ment for Ras-induced lung cancer. The importance of Ras-mediated PI3K activation in lung 
cancer and the efficacy of combined MAPK/PI3K inhibition in the KRas mouse model for 
lung cancer have been demonstrated previously37,61,62 which positively evaluates our RasE 
MultiHit mouse model.  
Inhibition of Ral might be bypassed by MAPK/PI3K cooperation. Moreover, in the 
absence of MAPK activation (or after inhibition of MAPK signaling by therapeutic interven-
tion), inhibition of Ral might promote rather than prevent formation of PI3K-driven lung 
tumors. Our findings further suggest that all three Ras effector pathways are required for 
development of lung tumor invasiveness in RasE mice. Continuing experiments in the RasE 
mouse model should elucidate if additional genetic hits (e.g. loss of Pten or p53) change 
the requirement of individual Ras effector pathways in lung tumorigenesis. These analyses 
might suggest alternative routes for combinatorial drug treatment of tumors depending 
on the individual genetic status.  
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8. Abbreviations 
 
APS   ammonium persulfate 
bp   base pairs 
DEPC   diethylpyrocarbonate 
DIG   digoxigenin  
DNA   deoxyribonucleic acid 
DTT   Dithiothreitol 
ECL    enzymatic chemiluminescence 
EDTA   ethylenediamine tetraacetic acid 
EtBr    etidium bromid 
EtOH   ethanol 
GAP   GTPase activating proteins 
GAPDH  glycerinaldehyde-3-phosphate-dehydrogenase 
GDP   guanosine diphosphate 
GEF   guanine nucleotide exchange factor 
GTP   guanosine triphosphate 
h   hour 
HCl   hydrochloric acid 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HISS   heat inactivated sheep serum 
IHC   immunohistochemistry 
ISH   in situ hybridization 
kb   kilo bases 
μ   micro (10-6) 
m   milli (10-3) 
M   molar 
MAPK   mitogen activated protein kinase 
min   minute 
MAPK   mitogen activated protein kinase 
MAPKK  mitogen activated protein kinase kinase 
MAPKKK  mitogen activated protein kinase kinase kinase 
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MPW   MiliPore water 
NaN3   sodium acide 
NaOH   sodium hydroxide 
NaPi    sodium phosphate buffer 
o/n   over night 
PBS   phosphate buffered saline 
PI3K   Phosphatidylinositol 3-kinases 
PCR   polymerase chain reaction 
rt   room temperature 
RTK   receptor tyrosine kinase 
SDS    sodium dodecyl sulfate 
SSC   saline sodium citrate 
TE    Tris/EDTA 
TEA   Triethanole amine 
TEMED  Tetramethylethylenediamine 
rpm   rotations per minute 
Tris   tris hydroxymethyl aminomethane 
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